Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Olix Pharmaceuticals Inc. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is being processed in 1 distinct art unit, indicating a specific technical niche for the company's current patent activity. The prosecution is overseen by a distinct examiner, concentrating the entire active workload with one individual. This structure reflects a very focused and streamlined interaction with the patent office during this period.
TATGE, LEXUS MARC is the busiest examiner for the company, holding the 1 pending office action. Because the company only has one pending office action, this examiner is the only one currently reviewing their applications. The focus on 1 distinct art unit and the distinct examiner simplifies the prosecution landscape to a single point of contact. There is no diversification of examiner risk, as the outcome of the entire active portfolio rests with this individual.
For a practitioner, the Biotechnology & Pharmaceuticals focus requires a strategy tailored to the specific standards of the assigned art unit. Since TATGE, LEXUS MARC manages the only active case, the applicant should prioritize understanding this examiner's past decisions and preferences. The resolution of the 1 pending office action will define the company's current patent trajectory. This focused environment allows for a dedicated legal effort on a single front rather than managing multiple disparate applications across the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TATGE, LEXUS MARC | 1 | 25.0% | +100.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18267885 | RNAI AGENT FOR INHIBITING HBV EXPRESSION AND USE THEREOF | TATGE, LEXUS MARC | 27d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18267885 | RNAI AGENT FOR INHIBITING HBV EXPRESSION AND USE THEREOF | TATGE, LEXUS MARC | 27d |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18267885 | RNAI AGENT FOR INHIBITING HBV EXPRESSION AND USE THEREOF | TATGE, LEXUS MARC | 1637 | §103§112 | Final Rejection | 27d | Pending | Jun 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOlix Pharmaceuticals Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Lexus Marc Tatge has the most, with 1 of Olix Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
